PD
MCID: PRK057
MIFTS: 81

Parkinson Disease, Late-Onset (PD)

Categories: Eye diseases, Genetic diseases, Mental diseases, Metabolic diseases, Muscle diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Parkinson Disease, Late-Onset

MalaCards integrated aliases for Parkinson Disease, Late-Onset:

Name: Parkinson Disease, Late-Onset 57 28 5 36 71
Parkinson Disease 57 11 24 19 42 73 28 53 5 43 38 71 31 33
Parkinson's Disease 11 42 52 75 41 14
Pd 57 42 73
Parkinson Disease, Susceptibility to 57 12
Late Onset Parkinson's Disease 11 14
Late Onset Parkinson Disease 11 73
Idiopathic Parkinson Disease 73 33
Primary Parkinsonism 42 73
Paralysis Agitans 11 73
Parkinson's 63 33
Park 57 73
Parkinson Disease, Late-Onset, Susceptibility to 57
Parkinson Disease, Age of Onset, Modifier 57
Idiopathic Parkinson's Disease 14
Lewy Body Parkinson Disease 73
Primary Parkinson Disease 33
Pd - [parkinson Disease] 33
Parkinson Disease Nos 33
Parkinson, Nos 33

Characteristics:


Inheritance:

Autosomal dominant 57

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
insidious onset
progressive disorder
onset mid to late adulthood
levodopa-responsive


HPO:

30
parkinson disease, late-onset:
Onset and clinical course progressive insidious onset


Classifications:



Summaries for Parkinson Disease, Late-Onset

MedlinePlus: 41 Parkinson's disease (PD) is a type of movement disorder. It happens when nerve cells in the brain don't produce enough of a brain chemical called dopamine. Sometimes it is genetic, but most cases do not seem to run in families. Exposure to chemicals in the environment might play a role. Symptoms begin gradually, often on one side of the body. Later they affect both sides. They include: Trembling of hands, arms, legs, jaw and face Stiffness of the arms, legs and trunk Slowness of movement Poor balance and coordination As symptoms get worse, people with the disease may have trouble walking, talking, or doing simple tasks. They may also have problems such as depression, sleep problems, or trouble chewing, swallowing, or speaking. There is no specific test for PD, so it can be difficult to diagnose. Doctors use a medical history and a neurological examination to diagnose it. PD usually begins around age 60, but it can start earlier. It is more common in men than in women. There is no cure for PD. A variety of medicines sometimes help symptoms dramatically. Surgery and deep brain stimulation (DBS) can help severe cases. With DBS, electrodes are surgically implanted in the brain. They send electrical pulses to stimulate the parts of the brain that control movement. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary: Parkinson Disease, Late-Onset, also known as parkinson disease, is related to hereditary late-onset parkinson disease and parkinson disease 3, autosomal dominant, and has symptoms including tremor, constipation and myoclonus. An important gene associated with Parkinson Disease, Late-Onset is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Parkinson's disease pathway and Degradation pathway of sphingolipids, including diseases. The drugs Idebenone and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include Brain, and related phenotypes are hallucinations and abnormal autonomic nervous system physiology

MedlinePlus Genetics: 42 Parkinson disease is a progressive disorder of the nervous system. The disorder affects several regions of the brain, especially an area called the substantia nigra that controls balance and movement.Often the first symptom of Parkinson disease is trembling or shaking (tremor) of a limb, especially when the body is at rest. Typically, the tremor begins on one side of the body, usually in one hand. Tremors can also affect the arms, legs, feet, and face. Other characteristic symptoms of Parkinson disease include rigidity or stiffness of the limbs and torso, slow movement (bradykinesia) or an inability to move (akinesia), and impaired balance and coordination (postural instability). These symptoms worsen slowly over time.Parkinson disease can also affect emotions and thinking ability (cognition). Some affected individuals develop psychiatric conditions such as depression and visual hallucinations. People with Parkinson disease also have an increased risk of developing dementia, which is a decline in intellectual functions including judgment and memory.Generally, Parkinson disease that begins after age 50 is called late-onset disease. The condition is described as early-onset disease if signs and symptoms begin before age 50. Early-onset cases that begin before age 20 are sometimes referred to as juvenile-onset Parkinson disease.

NINDS: 52 Parkinson's disease (PD) belongs to a group of conditions called motor system disorders, which cause unintended or uncontrollable movements of the body.  The precise cause of PD is unknown, but some cases are hereditary while others are thought to occur from a combination of genetics and environmental factors that trigger the disease.  In PD, brain cells become damaged or die in the part of the brain that produces dopamine--a chemical needed to produce smooth, purposeful movement. The four primary symptoms of PD are: tremor--shaking that has a characteristic rhythmic back and forth motion rigidity--muscle stiffness or a resistance to movement, where muscles remain constantly tense and contracted bradykinesia--slowing of spontaneous and automatic movement that can make it difficult to perform simple tasks or rapidly perform routine movements postural instability--impaired balance and changes in posture that can increase the risk of falls. Other symptoms may include difficulty swallowing, chewing, or speaking; emotional changes; urinary problems or constipation; dementia or other cognitive problems; fatigue; and problems sleeping. PD usually affects people around the age of 70 years but can occur earlier.  PD affects men more than women.  Currently there are no specific tests that diagnose sporadic PD.

UniProtKB/Swiss-Prot: 73 A complex neurodegenerative disorder characterized by bradykinesia, resting tremor, muscular rigidity and postural instability. Additional features are characteristic postural abnormalities, dysautonomia, dystonic cramps, and dementia. The pathology of Parkinson disease involves the loss of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies (intraneuronal accumulations of aggregated proteins), in surviving neurons in various areas of the brain. The disease is progressive and usually manifests after the age of 50 years, although early-onset cases (before 50 years) are known. The majority of the cases are sporadic suggesting a multifactorial etiology based on environmental and genetic factors. However, some patients present with a positive family history for the disease. Familial forms of the disease usually begin at earlier ages and are associated with atypical clinical features.

PubMed Health : 63 Parkinson's: Parkinson's is a disease of the nervous system that mostly affects older people. It typically begins after the age of 50. The disease can be very hard to live with because it severely restricts mobility and as a result makes daily activities increasingly difficult. Parkinson's is a progressive disease, which means that in most cases it will continue to gradually get worse. Many people who develop Parkinson’s will require nursing care. There is no cure for the disease and its exact cause is not known, but there are effective treatments that can relieve the symptoms.

OMIM®: 57 Parkinson disease was first described by James Parkinson in 1817. It is the second most common neurodegenerative disorder after Alzheimer disease (AD; 104300), affecting approximately 1% of the population over age 50 (Polymeropoulos et al., 1996). (168600) (Updated 08-Dec-2022)

Disease Ontology 11 Late onset parkinson's disease: A Parkinson's disease characterized by onset of motor symptoms typically after 60 years of age.

Parkinson's disease: A synucleinopathy that has material basis in degeneration of the central nervous system that often impairs motor skills, speech, and other functions.

Wikipedia: 75 Parkinson's disease (PD), or simply Parkinson's, is a long-term degenerative disorder of the central... more...

GeneReviews: NBK1223

Related Diseases for Parkinson Disease, Late-Onset

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 1, Autosomal Dominant Parkinson Disease 15, Autosomal Recessive Early-Onset
Parkinson Disease 12 Parkinson Disease 2, Autosomal Recessive Juvenile
Parkinson Disease 3, Autosomal Dominant Parkinson Disease 4, Autosomal Dominant
Parkinson Disease 6, Autosomal Recessive Early-Onset Parkinson Disease 7, Autosomal Recessive Early-Onset
Parkinson Disease 10 Parkinson Disease 8, Autosomal Dominant
Parkinson Disease 11, Autosomal Dominant Parkinson Disease 13, Autosomal Dominant
Parkinson Disease 14, Autosomal Recessive Parkinson Disease 16
Parkinson Disease 5, Autosomal Dominant Parkinson Disease 17
Parkinson Disease 18, Autosomal Dominant Parkinson Disease 19a, Juvenile-Onset
Parkinson Disease 20, Early-Onset Parkinson Disease 21
Parkinson Disease 22, Autosomal Dominant Parkinson Disease 23, Autosomal Recessive Early-Onset
Parkinson Disease 24, Autosomal Dominant Juvenile-Onset Parkinson's Disease
Early-Onset Parkinson's Disease Vps35-Related Parkinson Disease
Hereditary Late-Onset Parkinson Disease

Diseases related to Parkinson Disease, Late-Onset via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1855)
# Related Disease Score Top Affiliating Genes
1 hereditary late-onset parkinson disease 34.2 RFC1 PSAP NR4A2 MT-ND1 MAPT LRRK2
2 parkinson disease 3, autosomal dominant 33.7 PRKN MAPT LRRK2
3 parkinson disease 21 33.6 VPS13C PRKN LRRK2 DNAJC13
4 parkinson disease 15, autosomal recessive early-onset 33.3 PRKN LRRK2 DNAJC13
5 essential tremor 33.2 PRKN MAPT LRRK2 GBA1 DNAJC13 ATXN2
6 postencephalitic parkinson disease 33.1 PRKN MAPT LRRK2
7 multiple system atrophy 1 33.0 PRKN MAPT LRRK2 GBA1
8 nervous system disease 33.0 TBP PRKN NR4A2 MIR433 MAPT LRRK2
9 supranuclear palsy, progressive, 1 32.9 PRKN MAPT LRRK2 GBA1 ATXN2
10 kufor-rakeb syndrome 32.6 PRKN LRRK2 GBA1 DNAJC13
11 alzheimer disease, familial, 1 32.5 TBP PRKN NR4A2 MT-ND1 MAPT LRRK2
12 parkinson disease 2, autosomal recessive juvenile 32.4 VPS13C PRKN LRRK2
13 juvenile-onset parkinson's disease 32.4 PRKN DNAJC13
14 amyotrophic lateral sclerosis 1 32.2 TBP PRKN NR4A2 NEAT1 MAPT LRRK2
15 gaucher disease, type i 32.2 PSAP PRKN LRRK2 LOC106627981 GBA1
16 gaucher's disease 32.2 PSAP PRKN LRRK2 LOC106627981 GBA1
17 restless legs syndrome 31.8 TBP PRKN MAPT ATXN2
18 frontotemporal dementia 31.7 PRKN NEAT1 MAPT LRRK2 ATXN2
19 parkinsonism 31.6 TBP PRKN MAPT LRRK2 LOC106627981 GBA1
20 autosomal dominant cerebellar ataxia 31.6 TBP PRKN MAPT LRRK2 ATXN8OS ATXN2
21 movement disease 31.6 VPS13C TBP PRKN MAPT LRRK2 LOC106627981
22 hereditary spastic paraplegia 31.5 VPS13C PRKN MAPT LRRK2 GBA1 DNAJC13
23 cerebellar disease 31.4 TBP PRKN MAPT LRRK2 ATXN8OS ATXN2
24 vascular parkinsonism 31.4 PRKN LRRK2 GBA1
25 choreatic disease 31.4 VPS13C TBP PRKN LRRK2 ATXN2
26 early-onset parkinson's disease 31.4 VPS13C PRKN LRRK2 GBA1 DNAJC13
27 neuronal ceroid lipofuscinosis 31.4 PSAP PRKN MAPT LRRK2 GBA1 DNAJC13
28 pick disease of brain 31.4 PRKN MAPT LRRK2
29 hereditary ataxia 31.2 TBP PRKN ATXN8OS ATXN2
30 tremor 31.2 PRKN MAPT LRRK2 LOC106627981 GBA1
31 dementia 31.2 PRKN MT-ND1 MAPT LRRK2 LOC106627981 GBA1
32 gaucher disease, type iii 31.0 PSAP LOC106627981 GBA1
33 parkinson disease 1, autosomal dominant 31.0 LRRK2 GBA1 ATXN2
34 dementia, lewy body 30.9 VPS13C PRKN MAPT LRRK2 LOC106627981 GBA1
35 dentatorubral-pallidoluysian atrophy 30.9 TBP ATXN8OS ATXN2
36 gaucher disease, type ii 30.9 PSAP LOC106627981 GBA1
37 spinocerebellar ataxia 17 30.8 TBP ATXN8OS ATXN2
38 sphingolipidosis 30.8 PSAP PRKN LRRK2 GBA1
39 machado-joseph disease 30.7 TBP PRKN LRRK2 ATXN8OS ATXN2
40 rem sleep behavior disorder 30.6 PRKN MAPT LRRK2 GBA1
41 toxic encephalopathy 30.6 PRKN MAPT LRRK2
42 spinocerebellar ataxia 6 30.6 TBP ATXN8OS ATXN2
43 speech disorder 30.4 MAPT LOC106627981 GBA1
44 creutzfeldt-jakob disease 30.3 TBP MAPT LRRK2
45 spinocerebellar ataxia 37 30.2 RFC1 ATXN8OS
46 parkinson disease 19a, juvenile-onset 11.7
47 parkinson disease 18, autosomal dominant 11.7
48 parkinson disease 17 11.7
49 parkinson disease 20, early-onset 11.6
50 parkinson disease 23, autosomal recessive early-onset 11.6

Comorbidity relations with Parkinson Disease, Late-Onset via Phenotypic Disease Network (PDN): (show top 50) (show all 51)


Active Peptic Ulcer Disease Acute Conjunctivitis
Acute Cystitis Alzheimer Disease, Familial, 1
Anxiety Atypical Depressive Disorder
Autonomic Nervous System Disease Bipolar Disorder
Blepharitis Bronchitis
Bronchopneumonia Cerebral Atherosclerosis
Cerebral Degeneration Cerebrovascular Disease
Communicating Hydrocephalus Conjunctivitis
Cystitis Decubitus Ulcer
Deficiency Anemia Delusional Disorder
Dependent Personality Disorder Dysthymic Disorder
Early-Onset Generalized Limb-Onset Dystonia Encephalopathy
Erythematosquamous Dermatosis Esophagitis
Generalized Atherosclerosis Heart Disease
Hypothyroidism Iron Deficiency Anemia
Leukodystrophy Major Affective Disorder 9
Major Depressive Disorder Marasmus
Mood Disorder Neurogenic Bladder
Obstructive Hydrocephalus Osteoporosis
Paralytic Ileus Paranoid Schizophrenia
Pernicious Anemia Personality Disorder
Prostatic Hypertrophy Protein-Energy Malnutrition
Pseudobulbar Palsy Schizophrenia
Schizophreniform Disorder Swallowing Disorders
Tardive Dyskinesia Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Parkinson Disease, Late-Onset:



Diseases related to Parkinson Disease, Late-Onset

Symptoms & Phenotypes for Parkinson Disease, Late-Onset

Human phenotypes related to Parkinson Disease, Late-Onset:

30 (show all 24)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 hallucinations 30 Occasional (7.5%) HP:0000738
2 abnormal autonomic nervous system physiology 30 Occasional (7.5%) HP:0012332
3 sleep disturbance 30 HP:0002360
4 depression 30 HP:0000716
5 dysarthria 30 HP:0001260
6 tremor 30 HP:0001337
7 dysphagia 30 HP:0002015
8 constipation 30 HP:0002019
9 mask-like facies 30 HP:0000298
10 dystonia 30 HP:0001332
11 weak voice 30 HP:0001621
12 rigidity 30 HP:0002063
13 dementia 30 HP:0000726
14 personality changes 30 HP:0000751
15 postural instability 30 HP:0002172
16 urinary urgency 30 HP:0000012
17 parkinsonism 30 HP:0001300
18 neuronal loss in central nervous system 30 HP:0002529
19 bradykinesia 30 HP:0002067
20 resting tremor 30 HP:0002322
21 short stepped shuffling gait 30 HP:0007311
22 lewy bodies 30 HP:0100315
23 substantia nigra gliosis 30 HP:0011960
24 micrographia 30 HP:0031908

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Neurologic Behavioral Psychiatric Manifestations:
depression

Abdomen Gastrointestinal:
dysphagia
constipation

Head And Neck Face:
masked facies

Neurologic Central Nervous System:
dysarthria
dystonia
rigidity
postural instability
parkinsonism
more
Genitourinary Bladder:
urinary urgency

Head And Neck Nose:
decreased sense of smell

Clinical features from OMIM®:

168600 (Updated 08-Dec-2022)

UMLS symptoms related to Parkinson Disease, Late-Onset:


tremor; constipation; myoclonus; back pain; angina pectoris; headache; hyposmia; syncope; pain; bradykinesia; resting tremor; chronic pain; sciatica; sleep disturbances; seizures; vertigo/dizziness; equilibration disorder; sleeplessness; muscle rigidity; urgency of micturition

Drugs & Therapeutics for Parkinson Disease, Late-Onset

PubMed Health treatment related to Parkinson Disease, Late-Onset: 63

Parkinson 's is usually treated with medication. At the beginning of the disease – when the symptoms are not problematic – treatment is sometimes not necessary. If the symptoms get worse, medication can help. Treatment with medication generally aims to replace the lacking dopamine . That often relieves symptoms, but does not slow the progress of the disease. Because over time the drugs are no longer effective, the type and dose of medication has to be adjusted again and again. One option is to use a medication pump. It provides the drug either under the skin or directly into the small intestine and ensures a constant supply. Occupational therapy is used to practice everyday movements and activities. Restricted movement means that the muscles lose strength. Movement exercises (physiotherapy ) and sports aim to help counteract that and improve movement and coordination. Speech therapy can be an option if the voice becomes quieter and speech less clear. Deep brain stimulation is recommended to some people whose symptoms are not relieved enough by taking medication. That involves surgery to implant electrodes in certain parts of the brain. They continuously emit electrical impulses that influence muscle activity.

Drugs for Parkinson Disease, Late-Onset (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 499)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Idebenone Approved, Investigational Phase 4 58186-27-9 3686
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
4
Mirabegron Approved Phase 4 223673-61-8 18319735 9865528
5
Ropinirole Approved, Investigational Phase 4 91374-21-9 5095
6
Trimethobenzamide Approved, Investigational Phase 4 138-56-7 5577
7
Tolcapone Approved, Withdrawn Phase 4 134308-13-7 4659569
8
Sodium oxybate Approved Phase 4 502-85-2 23663870
9
Sulfamethazine Approved, Investigational, Vet_approved Phase 4 57-68-1 5327
10
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
11
Bromocriptine Approved, Investigational, Withdrawn Phase 4 25614-03-3 31101
12
Lubiprostone Approved, Investigational Phase 4 136790-76-6 656719 157920
13
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
14
Primaquine Approved Phase 4 90-34-6 4908
15
Piperaquine Approved, Experimental, Investigational Phase 4 4085-31-8
16
Pimavanserin Approved, Investigational Phase 4 706779-91-1 10071196
17
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
18
Benserazide Approved, Investigational Phase 4 322-35-0 2327
19
Opicapone Approved, Investigational Phase 4 923287-50-7 135565903
20
Zoledronic acid Approved Phase 4 118072-93-8 68740
21
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
22
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9, 14611-52-0 5195 26757
23
Vortioxetine Approved, Investigational Phase 4 508233-74-7 9966051
24
Donepezil Approved Phase 4 120014-06-4 3152
25
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
26
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
27
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
28
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
29
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
30
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
31
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
32
Topiramate Approved Phase 4 97240-79-4 5284627
33
Amitriptyline Approved Phase 4 50-48-6 2160
34
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
35
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
36
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
37
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
38
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
39
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 60857
40
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
41
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
42
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
43
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
44
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
45
Rasagiline Approved Phase 4 136236-51-6 3052776
46
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
47
Pramipexole Approved, Investigational Phase 4 104632-26-0, 104632-25-9, 104632-28-2 4885 119570 59868
48
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537 59227
49
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
50
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966

Interventional clinical trials:

(show top 50) (show all 3296)
# Name Status NCT ID Phase Drugs
1 Effect of Acetylcholinesterase Inhibitors on the Gait of the Patients With Parkinson Disease Characterized by Postural Instability and Gait Disturbance Unknown status NCT03011476 Phase 4 Donepezil;Placebos
2 An Open-label, Randomized, Multi-center, Crossover Study to Observe the Effect of Once-daily Mirapex ER® and Twice-daily Mirapex ER® in Patients With Parkinson Disease Unknown status NCT01515774 Phase 4 Mirapex ER
3 Effects of Different Concentrations of Dexmedetomidine on Basal Ganglia Neuronal Activity (Local Field Potentials) in Parkinson's Disease Unknown status NCT02982512 Phase 4 Dexmedetomidine
4 The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study) Unknown status NCT00354133 Phase 4 Best Medical Treatment
5 Mirabegron for Treatment of Overactive Bladder Symptoms in Patients With Parkinson's Disease: a Double-blind, Randomized Placebo-controlled Trial Unknown status NCT03412513 Phase 4 Mirabegron;Placebo
6 A Multicenter, Randomized, Double-blind, Placebo-controlled Study: Evaluation of the Efficacy and Safety of Agomelatine in the Treatment of Sleep Disorders and Depression in Patients With Parkinson's Disease Unknown status NCT03977441 Phase 4 Agomelatine or PIacebo
7 Effects of Azilect (Rasagiline) on Processing of Emotions, Mood and Executive Function in Parkinson's Disease Unknown status NCT01385735 Phase 4 Rasagiline;Placebo
8 A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Idebenone in the Treatment of Early-stage Parkinson's Disease With Motor and Non-motor Symptoms Unknown status NCT03727295 Phase 4 Idebenone/placebo
9 The Use of Toxin Botulinum A Toxin in Patients With Parkinson's Disease and Multiple System Disease, Affected by Refractory Detrusor Overactivity. Unknown status NCT00822913 Phase 4 Intravesical injection of Botulinum A toxin
10 Monitoring Anti-Dementia Drugs by Serum Levels: Importance of Serum Levels, Drug-monitoring, Side-effects, Clinical Efficacy and Compliance (Translation of Official Danish Title) Unknown status NCT04117178 Phase 4 Donepezil;Memantine
11 Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial Unknown status NCT02768077 Phase 4 Melatonin(Circadin®);Placebo
12 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months Unknown status NCT00696215 Phase 4 placebo;rasagiline
13 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
14 Effect of Melatonin on Sleep Disturbances in Patients With Parkinson's Disease: Double Blind, Randomized, Placebo Controlled Trial Unknown status NCT03258294 Phase 4 Melatonin(Circadin®);Placebo Oral Tablet
15 Wuling Powder for the Treatment and Underlying Mechanism of Depressive Symptoms in Patients With Parkinson's Disease: a Randomised, Double-blind, Placebo-controlled Trial. Unknown status NCT03195231 Phase 4 Wuling Powder;Placebo
16 A Prospective Randomized Placebo-Controlled Double-Blind Study Assessing Change in Olfactory Function After Initiation of Rasagiline in Idiopathic Parkinson's Disease Unknown status NCT01007630 Phase 4 Rasagiline;Placebo
17 A Prospective, Open Label, Single Arm, Clinical Study to Evaluate the Effect of Safinamide on Sleep Quality and Polysomnographic Parameters in Patients With Parkinson's Disease: the Safe Sleep Study Unknown status NCT03968744 Phase 4 Safinamide
18 Evaluation of the Efficacy of Rasagiline in Apathy in Drug-naïve Patients With Parkinson's Disease by a Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study. Unknown status NCT01765257 Phase 4 AZILECT®;Placebo
19 A Double Blind, Placebo-controlled Study for the Effect of IV Amantadine on Freezing of Gait (FOG) Resistant to Dopaminergic Therapy Unknown status NCT01313819 Phase 4 PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj
20 Role of Dopamine on Loss Aversion Behaviour: Study on Parkinsonian Patients. Unknown status NCT01780467 Phase 4
21 Nicotine Treatment of Impulsivity in Parkinson's Disease: A Pilot Study Unknown status NCT01216904 Phase 4 nicotine patch;placebo
22 An Open-label Trial of Oral Selegiline 5 or 10 mg and Tadalafil 2.5mg Co-administration to Male Patients With Parkinson's Disease and Moderate Erectile Dysfunction. Unknown status NCT02225548 Phase 4 Selegiline;Tadalafil
23 Effect of Deep Brain Stimulation on Gait of Patients With Parkinson's Disease Depending on Electrode Location in Subthalamic Area. Unknown status NCT01782638 Phase 4
24 Cholinergic Neurotransmission - A Common Underlying Mechanism of Cognitive and Gait Impairment in Parkinson Disease Completed NCT03840837 Phase 4 Rivastigmine transdermal patch
25 A Randomised Placebo-controlled Trial of Rasagiline in Parkinson Disease Patients With Symptoms of Apathy Completed NCT00755027 Phase 4 Rasagiline
26 A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition Completed NCT02536976 Phase 4 mirabegron;Placebo
27 An Open-label, Multi-center, Crossover Study to Compare the Effect of Once-daily Ropinirole PR and Twice-daily Ropinirole PR in Patients With Parkinson Disease Completed NCT00986245 Phase 4 Ropinirole Prolonged release
28 Norepinephrine-targeted Therapy for Action Control in Parkinson Disease Completed NCT03115827 Phase 4 Droxidopa;Carbidopa
29 Depression Diagnosis and Treatment in Parkinson Disease Completed NCT00304161 Phase 4 Atomoxetine;Placebo
30 Technology-Based Objective Measures for Gait and Postural Assessment in Parkinson Disease Patients With Orthostatic Hypotension: Feasibility and Effect-Size Finding Study Completed NCT04510922 Phase 4 Droxidopa 100 MG [Northera]
31 A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action Completed NCT01770145 Phase 4 APOKYN;L-dopa;Trimethobenzamide
32 A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis Completed NCT04292223 Phase 4 Pimavanserin
33 Post-Marketing Clinical Study of REQUIP (Ropinirole Hydrochloride) Tablets in Patients With Parkinson's Disease- Evaluation of Long-Term Efficacy and Safety - Completed NCT00485069 Phase 4 ROP;ROP+L-Dopa
34 A Randomised, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Safinamide 100mg Once Daily, as add-on Therapy, in Idiopathic Parkinson's Disease (PD) Patients With Motor Fluctuations and PD Related Chronic Pain Completed NCT03841604 Phase 4 Safinamide Methanesulfonate;Safinamide methanesulfonate matching placebo
35 Clinical and Pharmacokinetics Study to Evaluate the Therapeutic Equivalence and Bioequivalence of Levodopa Benserazide Generic Formulation (Teva Italia) Versus the Originator (Madopar®) Completed NCT02741947 Phase 4 Levodopa Benserazide Madopar;Levodopa Benserazide Teva Italia
36 An Open Label Pilot Study on the Tolerability of Duloxetine in the Treatment of Depressed Patients With Parkinson's Disease Completed NCT00437125 Phase 4 Duloxetine hydrochloride
37 Overnight Switch From Rasagiline To Safinamide In Fluctuating Patients With Parkinson's Disease: A Tolerability And Safety Study Completed NCT03843944 Phase 4 Safinamide
38 Effect of Short-term Motilitone Therapy on Health-related Quality of Life in Parkinson's Disease Patients With Gastrointestinal Symptoms: a Multicenter, Double-blind Randomized, Placebo-controlled Trial Completed NCT02775591 Phase 4 DA-9701;DA-9701 placebo
39 Efficacy of Levodopa/Benserazide Dispersible Tablet on Response Fluctuations in Parkinson's Disease Patients With Delayed ON: a Multicenter Randomized Open-label Cross-over Trial Completed NCT02769793 Phase 4 Levodopa dispersible;Levodopa
40 A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Efficacy Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over a 12-week Treatment Phase in Early Parkinson's Disease Patients (PramiBID) Completed NCT00402233 Phase 4 Pramipexole;Placebo
41 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
42 Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial Completed NCT00030979 Phase 4 Donepezil
43 Pharmacokinetics of Levodopa in Patients With Parkinson's Disease Treated With Levodopa/Carbidopa Infusion With and Without Oral COMT Inhibitors Completed NCT00906828 Phase 4 levodopa/carbidopa;entacapone;tolcapone
44 A Two Year Open Label, Randomized, Parallel Group, Blinded Assessment Ophthalmologic Safety Study of Pramipexole IR Versus Ropinirole in Early Parkinson's Disease Patients Completed NCT00144300 Phase 4 Mirapex;Requip
45 Randomized, Double-blind, Placebo-controlled Study of Naltrexone for Impulse Control Disorders in Parkinson's Disease Completed NCT01052831 Phase 4 Naltrexone;Placebo
46 A Two- Stage Multicenter, Open-label, Randomized, Active Controlled Parallel Group Study Comparing the Efficacy and Safety of Pramipexole SR Versus Pramipexole IR Administered Orally Over an 18-week Treatment on Nocturnal Symptoms in L-Dopa+ Treated Patients With Advanced Parkinson's Disease (PD) Completed NCT03521635 Phase 4 Pramipexole SR;Pramipexole IR
47 A Multi-center, Open-Label Study to Evaluate the Efficacy and Safety of Selegiline for the Treatment of Excessive Daytime Sleepiness in Parkinson's Disease Completed NCT04870372 Phase 4 Selegiline
48 A Randomized, Double-blind, Placebo-controlled, Parallel-group Clinical Trial to Examine the Efficacy and Safety of Early Pramipexole (PPX) Treatment Versus Delayed Pramipexole Treatment in Patients With New Onset Parkinson's Disease. Completed NCT00321854 Phase 4 pramipexole
49 A Randomized, Double-blind, Placebo-controlled, Parallel Group Efficacy Study of Pramipexole and Placebo Administered Orally Over a 12 Week Treatment Phase in Parkinson's Disease Patients With Stable Motor Function and Depressive Symptoms Completed NCT00297778 Phase 4 Pramipexole
50 Continuous Delivery of Levodopa/Carbidopa (Duodopa) in Patients With Advanced Idiopathic Parkinsons Disease - a Health Economic Evaluation Completed NCT00272688 Phase 4 Levodopa (drug), intraduodenal administration

Search NIH Clinical Center for Parkinson Disease, Late-Onset

Inferred drug relations via UMLS 71 / NDF-RT 50 :


2-Bromoergocryptine Mesylate
Amantadine
Amantadine Hydrochloride
Apomorphine
Apomorphine hydrochloride
Benztropine
benztropine mesylate
Biperiden
Biperiden Hydrochloride
biperiden lactate
Bromocriptine
cabergoline
Carbidopa
entacapone
Levodopa
Pergolide
Pergolide Mesylate
Pramipexole
Pramipexole dihydrochloride
ropinirole
Ropinirole hydrochloride
Selegiline
selegiline hydrochloride
tolcapone
Trihexyphenidyl
Trihexyphenidyl Hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Parkinson Disease, Late-Onset cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: parkinson disease

Genetic Tests for Parkinson Disease, Late-Onset

Genetic tests related to Parkinson Disease, Late-Onset:

# Genetic test Affiliating Genes
1 Parkinson Disease 28
2 Parkinson Disease, Late-Onset 28 ADH1C ATXN2 ATXN8OS GBA1 GLUD2 MAPT NR4A2 SNCAIP TBP

Anatomical Context for Parkinson Disease, Late-Onset

Organs/tissues related to Parkinson Disease, Late-Onset:

MalaCards : Brain, Subthalamic Nucleus, Bone Marrow, Globus Pallidus, Spinal Cord, Cortex, Eye
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Parkinson Disease, Late-Onset:
# Tissue Anatomical CompartmentCell Relevance
1 Brain Substantia Nigra pars Compacta Adult Dopaminergic Neurons Affected by disease, potential therapeutic candidate
2 Brain Forebrain White Matter Fibrous Astrocyte Cells Potential therapeutic candidate
3 Adipose Subcutaneous White Adipose Mesenchymal Stem Cells Potential therapeutic candidate
4 Brain Neocortex Protoplasmic Astrocyte Cells Potential therapeutic candidate
5 Adipose Subcutaneous White Adipose Stromal Cells Potential therapeutic candidate

Publications for Parkinson Disease, Late-Onset

Articles related to Parkinson Disease, Late-Onset:

(show top 50) (show all 63327)
# Title Authors PMID Year
1
Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. 53 62 57 5
19846850 2009
2
Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. 53 62 57 5
19286695 2009
3
Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. 53 62 57 5
18434642 2008
4
The need for appropriate genotyping strategies for glucocerebrosidase mutations in cohorts with Parkinson disease. 53 62 57 5
18541817 2008
5
Glucocerebrosidase gene mutations: a risk factor for Lewy body disorders. 53 62 57 5
18332251 2008
6
Glucocerebrosidase mutations and risk of Parkinson disease in Chinese patients. 53 62 57 5
17620502 2007
7
Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset. 62 57 5
19826450 2010
8
Differential effects of severe vs mild GBA mutations on Parkinson disease. 62 24 5
25653295 2015
9
Serotonin 2A receptors and visual hallucinations in Parkinson disease. 53 62 57
20385906 2010
10
Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. 53 62 5
18987351 2009
11
Glucocerebrosidase gene mutations and Parkinson disease in the Norwegian population. 53 62 57
16476943 2006
12
GSK3B polymorphisms alter transcription and splicing in Parkinson's disease. 53 62 57
16315267 2005
13
Mutations in the glucocerebrosidase gene and Parkinson's disease in Ashkenazi Jews. 53 62 57
15525722 2004
14
Genetic testing in spinocerebellar ataxia in Taiwan: expansions of trinucleotide repeats in SCA8 and SCA17 are associated with typical Parkinson's disease. 53 62 5
14756671 2004
15
Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. 53 62 57
14570706 2003
16
Identification and functional characterization of a novel R621C mutation in the synphilin-1 gene in Parkinson's disease. 53 62 57
12761037 2003
17
Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. 53 62 57
12669033 2003
18
Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. 53 62 57
12490535 2003
19
Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. 53 62 57
11710889 2001
20
Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. 53 62 57
11052933 2000
21
Genetic polymorphism of cytochrome P450 2D6 in idiopathic Parkinson disease and diffuse Lewy body disease. 53 62 57
9316701 1994
22
Association of a monoamine oxidase B allele with Parkinson's disease. 53 62 57
8489207 1993
23
Discriminating α-synuclein strains in Parkinson's disease and multiple system atrophy. 62 57
32025029 2020
24
Loss-of-Function NUBPL Mutation May Link Parkinson's Disease to Recessive Complex I Deficiency. 62 5
33224084 2020
25
Integrated Genetic Analysis of Racial Differences of Common GBA Variants in Parkinson's Disease: A Meta-Analysis. 62 5
29527153 2018
26
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease. 62 57
28882997 2017
27
β2-Adrenoreceptor is a regulator of the α-synuclein gene driving risk of Parkinson's disease. 62 57
28860381 2017
28
T cells from patients with Parkinson's disease recognize α-synuclein peptides. 62 57
28636593 2017
29
The discovery of LRRK2 p.R1441S, a novel mutation for Parkinson's disease, adds to the complexity of a mutational hotspot. 62 5
27111571 2016
30
Mutations of glucocerebrosidase gene and susceptibility to Parkinson's disease: An updated meta-analysis in a European population. 62 5
26868973 2016
31
ER Stress and Autophagic Perturbations Lead to Elevated Extracellular α-Synuclein in GBA-N370S Parkinson's iPSC-Derived Dopamine Neurons. 62 5
26905200 2016
32
Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. 62 5
26942284 2016
33
The MC1R melanoma risk variant p.R160W is associated with Parkinson disease. 62 57
25631192 2015
34
iPSC-derived dopamine neurons reveal differences between monozygotic twins discordant for Parkinson's disease. 62 5
25456120 2014
35
Glucocerebrosidase mutations in primary parkinsonism. 62 5
25249066 2014
36
The association between the LRRK2 G2385R variant and the risk of Parkinson's disease: a meta-analysis based on 23 case-control studies. 62 5
25027012 2014
37
Susceptibility loci for pigmentation and melanoma in relation to Parkinson's disease. 62 57
24439955 2014
38
Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. 62 5
24756352 2014
39
DNAJC13 mutations in Parkinson disease. 62 5
24218364 2014
40
LRRK2 G2385R and R1628P mutations are associated with an increased risk of Parkinson's disease in the Malaysian population. 62 5
25243190 2014
41
Mutations in GBA and risk of Parkinson's disease: a meta-analysis based on 25 case-control studies. 62 5
23676350 2013
42
The L444P GBA mutation is associated with early-onset Parkinson's disease in Mexican Mestizos. 62 5
23448517 2013
43
Greater risk of parkinsonism associated with non-N370S GBA1 mutations. 62 5
22968580 2013
44
The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation. 62 5
22612223 2012
45
Glucocerebrosidase N370S and L444P mutations as risk factors for Parkinson's disease in Brazilian patients. 62 5
22192918 2012
46
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. 62 5
22451204 2012
47
MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. 62 57
21558425 2011
48
Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. 62 57
21425343 2011
49
The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial. 62 57
21280081 2011
50
Large-scale screening of the Gaucher's disease-related glucocerebrosidase gene in Europeans with Parkinson's disease. 62 5
20947659 2011

Variations for Parkinson Disease, Late-Onset

ClinVar genetic disease variations for Parkinson Disease, Late-Onset:

5 (show top 50) (show all 117)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 VPS13C NM_020821.3(VPS13C):c.4777del (p.Gln1593fs) DEL Pathogenic
222071 rs869312811 GRCh37: 15:62239491-62239491
GRCh38: 15:61947292-61947292
2 VPS13C NM_020821.3(VPS13C):c.9568G>T (p.Glu3190Ter) SNV Pathogenic
222069 rs869312810 GRCh37: 15:62174851-62174851
GRCh38: 15:61882652-61882652
3 VPS13C NM_020821.3(VPS13C):c.8445+2T>G SNV Pathogenic
222067 rs869312809 GRCh37: 15:62207830-62207830
GRCh38: 15:61915631-61915631
4 VPS13C NM_020821.3(VPS13C):c.4165G>C (p.Gly1389Arg) SNV Pathogenic
222070 rs369100678 GRCh37: 15:62250807-62250807
GRCh38: 15:61958608-61958608
5 VPS13C NM_020821.3(VPS13C):c.806_807insCAGA (p.Arg269fs) INSERT Pathogenic
222068 rs879253853 GRCh37: 15:62305256-62305257
GRCh38: 15:62013057-62013058
6 LOC106627981, GBA NM_000157.4(GBA):c.1294T>A (p.Trp432Arg) SNV Pathogenic
599275 rs1557901552 GRCh37: 1:155205566-155205566
GRCh38: 1:155235775-155235775
7 LOC106627981, GBA NM_000157.4(GBA):c.762-1G>C SNV Pathogenic
633240 rs1237637353 GRCh37: 1:155207370-155207370
GRCh38: 1:155237579-155237579
8 GBA GRCh37/hg19 1q22(chr1:155188179-155209868) CN LOSS Pathogenic
813310 GRCh37: 1:155188179-155209868
GRCh38:
9 NR4A2 NM_006186.4(NR4A2):c.896G>T (p.Cys299Phe) SNV Pathogenic
1685988 GRCh37: 2:157185014-157185014
GRCh38: 2:156328502-156328502
10 GLUD2 NM_012084.4(GLUD2):c.1492T>G (p.Ser498Ala) SNV Pathogenic
29936 rs9697983 GRCh37: X:120183030-120183030
GRCh38: X:121049176-121049176
11 overlap with 6 genes NC_000014.9:g.(31394019_31414809)_(31654321_31655889)del DEL Pathogenic
929501 GRCh37: 14:31867179-32280475
GRCh38: 14:31394019-31655889
12 RFC1 (AAGGG)exp MICROSAT Pathogenic
1333160 GRCh37:
GRCh38: 4:39348425-39349149
13 LRRK2 NM_198578.4(LRRK2):c.4321C>A (p.Arg1441Ser) SNV Pathogenic
225276 rs33939927 GRCh37: 12:40704236-40704236
GRCh38: 12:40310434-40310434
14 MT-ND1 m.3397A>G SNV Pathogenic
9726 rs199476120 GRCh37: MT:3397-3397
GRCh38: MT:3397-3397
15 DNAJC13 NM_015268.4(DNAJC13):c.2564A>G (p.Asn855Ser) SNV Pathogenic
56171 rs387907571 GRCh37: 3:132196839-132196839
GRCh38: 3:132477995-132477995
16 LOC106627981, GBA1 NM_000157.4(GBA1):c.1448T>C (p.Leu483Pro) SNV Pathogenic
4288 rs421016 GRCh37: 1:155205043-155205043
GRCh38: 1:155235252-155235252
17 LOC106627981, GBA1 NM_000157.4(GBA1):c.1226A>G (p.Asn409Ser) SNV Pathogenic
Pathogenic
Risk Factor
4290 rs76763715 GRCh37: 1:155205634-155205634
GRCh38: 1:155235843-155235843
18 LOC106627981, GBA1 NM_000157.4(GBA1):c.1504C>T (p.Arg502Cys) SNV Pathogenic
Pathogenic
4295 rs80356771 GRCh37: 1:155204987-155204987
GRCh38: 1:155235196-155235196
19 LOC106627981, GBA1 NM_000157.4(GBA1):c.1604G>A (p.Arg535His) SNV Pathogenic
Pathogenic
4311 rs75822236 GRCh37: 1:155204793-155204793
GRCh38: 1:155235002-155235002
20 LOC106627981, GBA1 NM_000157.4(GBA1):c.1342G>C (p.Asp448His) SNV Pathogenic
Pathogenic
4293 rs1064651 GRCh37: 1:155205518-155205518
GRCh38: 1:155235727-155235727
21 LOC106627981, GBA1 NM_000157.4(GBA1):c.1297G>T (p.Val433Leu) SNV Pathogenic
Pathogenic
4292 rs80356769 GRCh37: 1:155205563-155205563
GRCh38: 1:155235772-155235772
22 LOC106627981, GBA1 NM_000157.4(GBA1):c.887G>A (p.Arg296Gln) SNV Pathogenic
Pathogenic
4328 rs78973108 GRCh37: 1:155207244-155207244
GRCh38: 1:155237453-155237453
23 GBA1 NM_000157.4(GBA1):c.115+1G>A SNV Pathogenic
Pathogenic/Likely Pathogenic
93445 rs104886460 GRCh37: 1:155210420-155210420
GRCh38: 1:155240629-155240629
24 MAPT NM_001377265.1(MAPT):c.2013T>G (p.Asn671Lys) SNV Pathogenic
14253 rs63750756 GRCh37: 17:44087690-44087690
GRCh38: 17:46010324-46010324
25 MAPT NM_001377265.1(MAPT):c.2078C>T (p.Pro693Leu) SNV Pathogenic
14245 rs63751273 GRCh37: 17:44087755-44087755
GRCh38: 17:46010389-46010389
26 MAPT NM_001377265.1(MAPT):c.2392C>T (p.Arg798Trp) SNV Pathogenic
14247 rs63750424 GRCh37: 17:44101427-44101427
GRCh38: 17:46024061-46024061
27 LRRK2 NM_198578.4(LRRK2):c.4321C>T (p.Arg1441Cys) SNV Pathogenic
1938 rs33939927 GRCh37: 12:40704236-40704236
GRCh38: 12:40310434-40310434
28 LRRK2 NM_198578.4(LRRK2):c.6055G>A (p.Gly2019Ser) SNV Pathogenic
1940 rs34637584 GRCh37: 12:40734202-40734202
GRCh38: 12:40340400-40340400
29 LOC106627981, GBA1 NM_000157.4(GBA1):c.1448T>C (p.Leu483Pro) SNV Pathogenic
4297 rs421016 GRCh37: 1:155205043-155205043
GRCh38: 1:155235252-155235252
30 GBA1 NM_000157.4(GBA1):c.84dup (p.Leu29fs) DUP Pathogenic
4302 rs387906315 GRCh37: 1:155210451-155210452
GRCh38: 1:155240660-155240661
31 LOC106627981, GBA1 NM_000157.4(GBA1):c.653G>A (p.Trp218Ter) SNV Pathogenic
632834 rs867929413 GRCh37: 1:155208033-155208033
GRCh38: 1:155238242-155238242
32 PSAP NM_002778.4(PSAP):c.470A>G (p.Asn157Ser) SNV Pathogenic
870633 rs756379007 GRCh37: 10:73588740-73588740
GRCh38: 10:71828983-71828983
33 LOC106627981, GBA1 NM_000157.4(GBA1):c.635C>G (p.Ser212Ter) SNV Pathogenic
996254 rs1671872221 GRCh37: 1:155208051-155208051
GRCh38: 1:155238260-155238260
34 LOC106627981, GBA1 NM_000157.4(GBA1):c.604C>T (p.Arg202Ter) SNV Pathogenic
1119997 GRCh37: 1:155208082-155208082
GRCh38: 1:155238291-155238291
35 LOC106627981, GBA1 NM_000157.4(GBA1):c.764T>A (p.Phe255Tyr) SNV Pathogenic/Likely Pathogenic
4298 rs74500255 GRCh37: 1:155207367-155207367
GRCh38: 1:155237576-155237576
36 LOC106627981, GBA1 NM_000157.4(GBA1):c.1312G>C (p.Asp438His) SNV Likely Pathogenic
1319931 GRCh37: 1:155205548-155205548
GRCh38: 1:155235757-155235757
37 LOC108663987, ATXN3 NM_004993.6(ATXN3):c.892CAG[8_36] MICROSAT Risk Factor
3551 rs193922928 GRCh37: 14:92537355-92537357
GRCh38: 14:92071011-92071013
38 LRRK2 NM_198578.4(LRRK2):c.7153G>A (p.Gly2385Arg) SNV Risk Factor
1943 rs34778348 GRCh37: 12:40757328-40757328
GRCh38: 12:40363526-40363526
39 MAPT NM_001377265.1(MAPT):c.2060ATA[1] (p.Asn688del) MICROSAT Risk Factor
98243 rs63751392 GRCh37: 17:44087737-44087739
GRCh38: 17:46010371-46010373
40 LOC106627981, GBA1 NM_000157.4(GBA1):c.946C>T (p.Arg316Cys) SNV Likely Pathogenic
813338 rs1264734195 GRCh37: 1:155207185-155207185
GRCh38: 1:155237394-155237394
41 DNAJB6 NM_058246.4(DNAJB6):c.577A>G (p.Thr193Ala) SNV Likely Pathogenic
870632 rs770053224 GRCh37: 7:157177659-157177659
GRCh38: 7:157384965-157384965
42 LOC106627981, GBA1 NM_000157.4(GBA1):c.1093G>A (p.Glu365Lys) SNV Risk Factor
199044 rs2230288 GRCh37: 1:155206167-155206167
GRCh38: 1:155236376-155236376
43 TNK2 NM_001382273.1(TNK2):c.2675G>A (p.Arg892His) SNV Likely Pathogenic
224859 rs112384084 GRCh37: 3:195594494-195594494
GRCh38: 3:195867623-195867623
44 LOC106627981, GBA NM_000157.4(GBA):c.1444G>A (p.Asp482Asn) SNV Risk Factor
4335 rs75671029 GRCh37: 1:155205047-155205047
GRCh38: 1:155235256-155235256
45 LOC108663996, TBP NG_008165.1:g.12526CAR[(46_?)] MICROSAT Risk Factor
562072 GRCh37:
GRCh38: 6:170561908-170561908
46 ATXN8OS, ATXN8 NR_002717.2(ATXN8OS):n.1103CTG[(107_127)] MICROSAT Risk Factor
562101 GRCh37:
GRCh38:
47 ATXN2 NP_002964.3:p.Gln166(>=33) MICROSAT Risk Factor
65668 GRCh37:
GRCh38:
48 PARK7 NM_007262.5(PARK7):c.399G>C (p.Met133Ile) SNV Uncertain Significance
96726 rs398124657 GRCh37: 1:8037788-8037788
GRCh38: 1:7977728-7977728
49 VPS35 NM_018206.6(VPS35):c.1576C>T (p.Arg526Cys) SNV Uncertain Significance
96727 rs398124658 GRCh37: 16:46702913-46702913
GRCh38: 16:46669001-46669001
50 PINK1 NM_032409.3(PINK1):c.644C>T (p.Pro215Leu) SNV Uncertain Significance
96728 rs371854396 GRCh37: 1:20964591-20964591
GRCh38: 1:20638098-20638098

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease, Late-Onset:

73
# Symbol AA change Variation ID SNP ID
1 PRKN p.Arg42Pro VAR_019736 rs368134308
2 PRKN p.Cys253Tyr VAR_019749 rs747427602
3 PRKN p.Arg256Cys VAR_019750 rs150562946
4 PRKN p.Arg275Trp VAR_019752 rs34424986
5 PRKN p.Asp280Asn VAR_019753 rs72480422

Copy number variations for Parkinson Disease, Late-Onset from CNVD:

6 (show all 18)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 23691 1 173049146 173078950 Copy number PAPPA2 Parkinson disease
2 27433 1 20832534 20850591 Genomic rearrangements PINK1 Parkinson disease
3 60306 11 84948993 84958207 Copy number DLG2 Parkinson disease
4 115237 17 55581582 55809920 Copy number USP32 Parkinson disease
5 132540 19 59310648 59326954 Genomic rearrangements PRPF31 Parkinson disease
6 170895 3 161200000 193800000 Copy number EIF4G1 Parkinson disease
7 186570 4 36900000 88200000 Duplication or triplication SNCA Parkinson disease
8 187375 4 48300000 99100000 Copy number SNCA Parkinson disease
9 189219 4 71528873 71716513 Copy number ENAM Parkinson disease
10 190419 4 88200000 94000000 Triplication SNCA Parkinson disease
11 190793 4 90645250 90759447 Duplication SNCA Parkinson disease
12 190807 4 90865727 90978470 Duplication or triplication SNCA Parkinson disease
13 207784 6 161000000 164500000 Gain or loss PRKN Parkinson disease
14 207856 6 161768590 163148834 Copy number PRKN Parkinson disease
15 207937 6 162471089 162677104 Copy number PRKN Parkinson disease
16 211738 6 336751 356443 Deletion IRF4 Parkinson disease
17 237664 8 25038472 25171648 Copy number Parkinson disease
18 195489 5 151389412 151513092 Copy number GLRA1 Parkinson disease

Expression for Parkinson Disease, Late-Onset

Search GEO for disease gene expression data for Parkinson Disease, Late-Onset.

Pathways for Parkinson Disease, Late-Onset

Pathways related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.38 PRKN LRRK2 ATXN2
2 10.1 PSAP GBA1

GO Terms for Parkinson Disease, Late-Onset

Biological processes related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron death GO:1901215 9.85 PRKN LRRK2 GBA1
2 regulation of dopamine metabolic process GO:0042053 9.76 PRKN NR4A2
3 cellular response to manganese ion GO:0071287 9.73 PRKN LRRK2
4 protein localization to mitochondrion GO:0070585 9.71 PRKN LRRK2
5 regulation of mitochondrial fission GO:0090140 9.62 MAPT LRRK2
6 intracellular distribution of mitochondria GO:0048312 9.56 LRRK2 MAPT
7 mitochondrion organization GO:0007005 9.56 VPS13C PRKN LRRK2 GBA1
8 regulation of synaptic vesicle endocytosis GO:1900242 9.48 PRKN LRRK2
9 regulation of synaptic vesicle transport GO:1902803 9.46 PRKN LRRK2
10 regulation of autophagy GO:0010506 9.23 PSAP PRKN MAPT LRRK2

Molecular functions related to Parkinson Disease, Late-Onset according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 tubulin binding GO:0015631 9.02 PRKN MAPT LRRK2

Sources for Parkinson Disease, Late-Onset

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....